ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib
Sign Up to like & getrecommendations! Published in 2019 at "Medicine"
DOI: 10.1097/md.0000000000014826
Abstract: Rationale: The anaplastic lymphoma kinase (ALK) rearrangements represent a subtype of nonsmall-cell lung cancer (NSCLC), and targeting ALK has radically changed the treatment of NSCLC. Crizotinib, as an ALK inhibitor, has been used in the… read more here.
Keywords: crizotinib; lung; alk; treatment ... See more keywords